Abstract
BackgroundIL-2 is a critical cytokine driving immune mediated killing of tumor cells by stimulating both the innate and adaptive immune cells. High-dose IL-2 (aldesleukin) has been approved for the treatment...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
